Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Return on Equity (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Return on Equity data on record, last reported at 0.57% in Q3 2025.

  • For Q3 2025, Return on Equity fell 8.0% year-over-year to 0.57%; the TTM value through Sep 2025 reached 0.57%, down 8.0%, while the annual FY2024 figure was 0.43%, 21.0% up from the prior year.
  • Return on Equity reached 0.57% in Q3 2025 per ZNTL's latest filing, up from 0.57% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.46% in Q1 2024 and bottomed at 0.71% in Q1 2025.
  • Average Return on Equity over 4 years is 0.54%, with a median of 0.54% recorded in 2023.
  • Peak YoY movement for Return on Equity: grew 12bps in 2024, then dropped -25bps in 2025.
  • A 4-year view of Return on Equity shows it stood at 0.51% in 2022, then decreased by -17bps to 0.6% in 2023, then rose by 20bps to 0.48% in 2024, then dropped by -18bps to 0.57% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 0.57% in Q3 2025, 0.57% in Q2 2025, and 0.71% in Q1 2025.